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Background: Low HDL levels are associated with increased cardiac mortality and infusion of reconstituted HDL shortens cardiac repolarization in 
isolated rabbit cardiomyocytes, dyslipidemic patients and healthy volunteers. However, whether low HDL is associated with increased sudden cardiac 
death (SCD) risk in hypertensive patients is unclear.
Methods: SCD risk was examined in relation to in-treatment HDL levels in 8606 hypertensive patients randomly assigned to losartan- or atenolol-
based treatment. HDL at each year of testing was categorized into the lowest quartile vs upper 3 quartiles according to baseline HDL levels or 
examined as a continuous variable with hazard ratios calculated for each SD of the baseline mean lower HDL (0.44 mmol/l).
Results: During 4.8±0.9 years follow-up, there were 168 SCD (2.0%). In univariate Cox analyses, compared with HDL ≥1.21 mmol/l, in-treatment 
HDL <1.21 was associated with a 101% greater risk of SCD (95% CI 48-174%, p<0.001). In parallel analyses using in-treatment HDL as a 
continuous variable, each 1 SD lower HDL was associated with a 85% higher SCD risk (95% CI 50-177%, p<0.001). In multivariate Cox analyses 
adjusting for randomized treatment, age, sex, body mass index, prevalent and history of atrial fibrillation and diabetes, history of MI, ischemic 
heart disease, stroke, peripheral vascular disease, smoking status, baseline serum creatinine, glucose, urine albumin/creatinine ratio as standard 
risk factors and for statin use, incident MI, in-treatment diastolic and systolic pressure, heart rate, QRS duration, Cornell product criteria for left 
ventricular hypertrophy and non-HDL cholesterol levels as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with 
a 49% greater risk of SCD (95% CI 6-109%, p=0.022) and, in alternative analyses, each 1 SD lower HDL treated as a continuous variable remained 
predictive of a 39% higher risk of SCD (95% CI 11-75%, p=0.004).
Conclusions: Lower in-treatment HDL is an independent predictor of SCD in hypertensive patients, even after adjusting for other potential risk 
factors and treatment effects. Whether increasing HDL levels can reduce the risk of SCD requires further evaluation.
